Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for CBGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
August 31, 2025 0.00
May 31, 2025 0.00
February 28, 2025 -0.0651M
November 30, 2024 0.0651M
August 31, 2024 0.00
May 31, 2024 0.00
February 29, 2024 0.0651M
November 30, 2023 0.00
August 31, 2023 0.00
May 31, 2023 0.0235M
February 28, 2023 -0.0543M
November 30, 2022 0.0551M
August 31, 2022 0.0628M
May 31, 2022 -0.156M
February 28, 2022 0.6699M
November 30, 2021 0.0595M
August 31, 2021 -0.0872M
May 31, 2021 0.69M
February 28, 2021 0.5516M
November 30, 2020 0.3525M
August 31, 2020
May 31, 2020 0.4632M
February 29, 2020 0.4331M
November 30, 2019 0.095M
August 31, 2019 0.2423M
Date Value
May 31, 2019 0.0131M
February 28, 2019 0.00
November 30, 2018 0.0154M
August 31, 2018 0.007M
May 31, 2018 0.0233M
February 28, 2018 0.00
November 30, 2017 0.0052M
August 31, 2017 0.00
May 31, 2017 0.00
February 28, 2017 0.00
November 30, 2016 0.00
August 31, 2016 0.00
May 31, 2016 0.00
February 29, 2016 0.00
November 30, 2015 0.00
August 31, 2015 0.00
May 31, 2015 0.00
February 28, 2015 0.00
November 30, 2014 0.00
August 31, 2014 0.00
May 31, 2014 0.00
February 28, 2014 0.07M
November 30, 2013 0.00
August 31, 2013 0.00
May 31, 2013 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Filana Therapeutics, Inc. -0.016M
CorMedix, Inc. -6.894M
Eloxx Pharmaceuticals, Inc. 60.39M
Breakthrough Chemistry, Inc. 0.00
BioStem Technologies, Inc. -1.146M

Cash from Financing (Quarterly) Related Metrics